Literature DB >> 33289681

Human and Veterinary Vaccines for Lyme Disease.

Nathaniel S O'Bier1, Amanda L Hatke1, Andrew C Camire1, Richard T Marconi1.   

Abstract

Lyme disease (LD) is an emerging zoonotic infection that is increasing in incidence in North America, Europe, and Asia. With the development of safe and efficacious vaccines, LD can potentially be prevented. Vaccination offers a cost-effective and safe approach for decreasing the risk of infection. While LD vaccines have been widely used in veterinary medicine, they are not available as a preventive tool for humans. Central to the development of effective vaccines is an understanding of the enzootic cycle of LD, differential gene expression of Borrelia burgdorferi in response to environmental variables, and the genetic and antigenic diversity of the unique bacteria that cause this debilitating disease. Here we review these areas as they pertain to past and present efforts to develop human, veterinary, and reservoir targeting LD vaccines. In addition, we offer a brief overview of additional preventative measures that should employed in conjunction with vaccination.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33289681      PMCID: PMC7946718          DOI: 10.21775/cimb.042.191

Source DB:  PubMed          Journal:  Curr Issues Mol Biol        ISSN: 1467-3037            Impact factor:   2.081


  300 in total

1.  Development of polymerase chain reaction primer sets for diagnosis of Lyme disease and for species-specific identification of Lyme disease isolates by 16S rRNA signature nucleotide analysis.

Authors:  R T Marconi; C F Garon
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

2.  Evidence that the BBA68 protein (BbCRASP-1) of the Lyme disease spirochetes does not contribute to factor H-mediated immune evasion in humans and other animals.

Authors:  John V McDowell; Kelley M Hovis; Hongming Zhang; Emily Tran; Justin Lankford; R T Marconi
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  Plasmid analysis and restriction fragment length polymorphisms of chromosomal DNA allow a distinction between Borrelia burgdorferi strains.

Authors:  M Stålhammar-Carlemalm; E Jenny; L Gern; A Aeschlimann; J Meyer
Journal:  Zentralbl Bakteriol       Date:  1990-10

4.  Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2.

Authors:  M Hirschfeld; C J Kirschning; R Schwandner; H Wesche; J H Weis; R M Wooten; J J Weis
Journal:  J Immunol       Date:  1999-09-01       Impact factor: 5.422

5.  Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.

Authors:  Steven D Lovrich; Dean A Jobe; Ronald F Schell; Steven M Callister
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

6.  Protective immunization with plasmid DNA containing the outer surface lipoprotein A gene of Borrelia burgdorferi is independent of an eukaryotic promoter.

Authors:  M M Simon; L Gern; P Hauser; W Zhong; P J Nielsen; M D Kramer; C Brenner; R Wallich
Journal:  Eur J Immunol       Date:  1996-12       Impact factor: 5.532

Review 7.  Lyme nephritis.

Authors:  Meryl P Littman
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2013-03-05

8.  Peptide-based OspC enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis.

Authors:  M J Mathiesen; M Christiansen; K Hansen; A Holm; E Asbrink; M Theisen
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

9.  Changes in infectivity and plasmid profile of the Lyme disease spirochete, Borrelia burgdorferi, as a result of in vitro cultivation.

Authors:  T G Schwan; W Burgdorfer; C F Garon
Journal:  Infect Immun       Date:  1988-08       Impact factor: 3.441

10.  OspA immunization decreases transmission of Borrelia burgdorferi spirochetes from infected Peromyscus leucopus mice to larval Ixodes scapularis ticks.

Authors:  J Tsao; A G Barbour; C J Luke; E Fikrig; D Fish
Journal:  Vector Borne Zoonotic Dis       Date:  2001       Impact factor: 2.133

View more
  5 in total

Review 1.  Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights.

Authors:  Wen-Hsiang Chen; Ulrich Strych; Maria Elena Bottazzi; Yi-Pin Lin
Journal:  Expert Rev Vaccines       Date:  2022-07-22       Impact factor: 5.683

2.  Abundance of Ixodes ricinus Ticks (Acari: Ixodidae) and the Diversity of Borrelia Species in Northeastern Poland.

Authors:  Katarzyna Kubiak; Hanna Szymańska; Małgorzata Dmitryjuk; Ewa Dzika
Journal:  Int J Environ Res Public Health       Date:  2022-06-16       Impact factor: 4.614

Review 3.  Recent Progress in Lyme Disease and Remaining Challenges.

Authors:  Jason R Bobe; Brandon L Jutras; Elizabeth J Horn; Monica E Embers; Allison Bailey; Robert L Moritz; Ying Zhang; Mark J Soloski; Richard S Ostfeld; Richard T Marconi; John Aucott; Avi Ma'ayan; Felicia Keesing; Kim Lewis; Choukri Ben Mamoun; Alison W Rebman; Mecaila E McClune; Edward B Breitschwerdt; Panga Jaipal Reddy; Ricardo Maggi; Frank Yang; Bennett Nemser; Aydogan Ozcan; Omai Garner; Dino Di Carlo; Zachary Ballard; Hyou-Arm Joung; Albert Garcia-Romeu; Roland R Griffiths; Nicole Baumgarth; Brian A Fallon
Journal:  Front Med (Lausanne)       Date:  2021-08-18

4.  Comparative analysis of antibody responses to outer surface protein (Osp)A and OspC in dogs vaccinated with Lyme disease vaccines.

Authors:  A C Camire; A L Hatke; V L King; J Millership; D M Ritter; N Sobell; A Weber; R T Marconi
Journal:  Vet J       Date:  2021-04-14       Impact factor: 2.688

5.  High-resolution crystal structure of the Borreliella burgdorferi PlzA protein in complex with c-di-GMP: new insights into the interaction of c-di-GMP with the novel xPilZ domain.

Authors:  Avinash Singh; Jerilyn R Izac; Edward J A Schuler; Dhara T Patel; Christopher Davies; Richard T Marconi
Journal:  Pathog Dis       Date:  2021-06-29       Impact factor: 3.166

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.